Vaccines and Kawasaki disease

References

• Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–276.
   PubMed Web of Science ®Google Scholar
• Sehgal S, Chen X, Ang JY. Epidemiology, clinical presentation, and outcomes of Kawasaki disease among hospitalized children in an inner city hospital before and after publication of the American Academy of Pediatrics/American Heart Association guidelines for treatment of Kawasaki disease: an 11-year period. Clin Pediatr. (Phila). 2015;54:1283–1289.
   Google Scholar
• Principi N, Rigante D, Esposito S. The role of infection in Kawasaki syndrome. J Infect. 2013;67:1–10.
   PubMed Web of Science ®Google Scholar
• Onouchi Y. Genetics of Kawasaki disease: what we know and don’t know. Circ J. 2012;76:1581–1586.
   PubMed Web of Science ®Google Scholar
• Ivars F. Superantigen-induced regulatory T cells in vivo. Chem Immunol Allergy. 2007;93:137–160.
   PubMedGoogle Scholar
• Jin HS, Kim HB, Kim BS, et al. The IL-10 (−627 A/C) promoter polymorphism may be associated with coronary aneurysms and low serum albumin in Korean children with Kawasaki disease. Pediatr Res. 2007;61:584–587.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Fukaya T. The role of superantigens of group A Streptococcus and Staphylococcus aureus in Kawasaki disease. Curr Opin Infect Dis. 2007;20:298–303.
   PubMed Web of Science ®Google Scholar
• Onouchi Y, Ozaki K, Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012 Mar 25;44(5):517–521. DOI:10.1038/ng.2220.
   PubMed Web of Science ®Google Scholar
• Lee YC, Kuo HC, Chang JS, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet. 2012;44:522–525.
   PubMed Web of Science ®Google Scholar
• Guo MM, Tseng WN, Ko CH, et al. Th17- and treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 2015;70:310–318.
   PubMed Web of Science ®Google Scholar
• Nagy G, Huszthy PC, Fossum E, et al. Selected aspects in the pathogenesis of autoimmune diseases. Mediators Inflamm. 2015;2015:351732.
   Web of Science ®Google Scholar
• McKinnon JE, Maksimowicz-McKinnon K. Autoimmune disease and vaccination: impact on infectious disease prevention and a look at future applications. Transl Res. 2015 Sep 5. pii: S1931-5244(15)00294-7. doi:10.1016/j.trsl.2015.08.008. [Epub ahead of print]
   Google Scholar
• Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunization with epatitis B vaccine. Clin Rheumatol. 2003;22:461–463.
   PubMed Web of Science ®Google Scholar
• Tredwell TA, Maddox RA, Holman RC, et al. Investigation of Kawasaki syndrome risk factors in Colorado. Pediatr Infect Dis J. 2002;21:976–978.
   PubMed Web of Science ®Google Scholar
• Hua W, Izurieta HS, Slade B, et al. Kawasaki disease after vaccination. Reports to the vaccine adverse event reporting system 1990–2007. Pediatr Infect Dis J. 2009;28:943–947.
   PubMed Web of Science ®Google Scholar
• Schmöeller D, Keiserman MW, Staub HL, et al. Yellow fever vaccination and Kawasaki disease. Pediatr Infect Dis J. 2009;28:1037–1038.
   PubMed Web of Science ®Google Scholar
• Uhlig U, Kostev K, Schuster V, et al. Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines. Pediatr Infect Dis J. 2014;33:e299–304.
   PubMed Web of Science ®Google Scholar
• Yeter D, Deth R. ITPKC susceptibility in Kawasaki syndrome as a sensitizing factor for autoimmunity and coronary arterial wall relaxation induced by thimerosal’s effects on calcium signaling via IP3. Autoimmun Rev. 2012;11:903–908.
   PubMed Web of Science ®Google Scholar
• Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40:35–42.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Yang KD, Juo SH, et al. ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One. 2011;6:e17370.
   PubMed Web of Science ®Google Scholar
• Abrams JY, Weintraub ES, Baggs JM, et al. Childhood vaccines and Kawasaki disease, vaccine safety datalink, 1996-2006. Vaccine. 2015;33:382–387.
   PubMed Web of Science ®Google Scholar
• Siegrist CA. Vaccine immunology. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008. p. 17–36.
   Google Scholar
• Klein NP, Lewis E, Fireman B, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015;135:e321–e329.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Klein NP, Dekker CL, et al. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012;31:271–277.
   PubMed Web of Science ®Google Scholar
• Center KJ, Hansen JR, Lewis E, et al. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009;28:438–440.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Vaccines, blood & biologics. Thimerosal in vaccines; [ cited 2015 Oct 13]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096228#t1
   Google Scholar
• Newburger JW, Takahashi M, Gerber MA, et al. Committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics. 2004;114:1708–1733.
   PubMed Web of Science ®Google Scholar
• Rowley AH. The complexities of the diagnosis and management of Kawasaki disease. Infect Dis Clin North Am. 2015;29:525–537.
   PubMed Web of Science ®Google Scholar
• De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301–308.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2011;60(RR–2):1–61.
   Google Scholar
• Tacke CE, Smits GP, Van Der Klis FR, et al. Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease. J Allergy Clin Immunol. 2013;131:1701–1703.
   PubMed Web of Science ®Google Scholar
• Canadian Immunization Guide Part 1. Ottawa: Public Health Agency of Canada; 2014.
   Google Scholar
• Key Immunization Information 2013. [ cited 2015 Oct 13]. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-10-eng.php
   Google Scholar
• Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr. 1993;122:204–211.
   PubMed Web of Science ®Google Scholar
• Pirofsky B, Campbell SM, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. J Clin Immunol. 1982;2(2 Suppl):7S–14S.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser permanente measles vaccine trial team. Pediatrics. 1996;97:53–58.
   PubMed Web of Science ®Google Scholar
• Kuijpers TW, Wiegman A, van Lier RA, et al. Kawasaki disease: a maturational defect in immune responsiveness. J Infect Dis. 1999;180:1869–1877.
   PubMed Web of Science ®Google Scholar
• Arvas A. Vaccination in patients with immunosuppression. Turk Pediatri Ars. 2014;49:181–185.
   PubMedGoogle Scholar
• Ljugman P. Vaccination of immunocompromised hosts. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccines. 6th ed. Philadelphia, PA: Saunders Elsevier; 2013. p. 1243–1256.
   Google Scholar
• Miura M, Katada Y, Ishihara J. Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin. Eur J Pediatr. 2004;163:25–29.
   PubMed Web of Science ®Google Scholar
• Lee G, Lee SE, Hong YM, et al. Is high-dose aspirin necessary in the acute phase of Kawasaki disease? Korean Circ J. 2013;43:182–186.
   PubMed Web of Science ®Google Scholar
• Onouchi Z, Kawasaki T. Overview of pharmacological treatment of Kawasaki disease. Drugs. 1999;58:813–822.
   PubMed Web of Science ®Google Scholar
• Sánchez-Manubens J, Bou R, Anton J. Diagnosis and classification of Kawasaki disease. J Autoimmun. 2014;48–49:113–117.
   PubMed Web of Science ®Google Scholar
• Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye’s syndrome and medication use. JAMA. 1982;248:687–691.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Olsen SJ, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep. 2015;64:818–825.
   PubMed Web of Science ®Google Scholar
• Principi N, Senatore L, Esposito S. Protection of young children from influenza through universal vaccination. Hum Vaccin Immunother. 2015;11:2350–2358.
   PubMed Web of Science ®Google Scholar
• Hsieh KS, Weng KP, Lin CC, et al. Treatment of acute kawasaki disease: aspirin’s role in the febrile stage revisited. Pediatrics. 2004;114:e689–e693.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin LY, Yang KD, et al. Kawasaki disease with G6PD deficiency–report of one case and literature review. J Microbiol Immunol Infect. 2014;47:261–263.
   PubMedGoogle Scholar
• Pickering LK, editor. Committee on infectious diseases red book: 2003 report of committee on infectious disease. Elk Grove Village (IL): American Academy of Pediatrics; 2003.
   Google Scholar
• Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the platelet inhibition in children on cLOpidogrel (PICOLO) trial. Circulation. 2008;117:553–559.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccines and immunizations. Contraindications and precautions for varicella vaccination. Information for healthcare providers. [ cited 2015 Oct 14]. Available from: http://www.cdc.gov/vaccines/vpd-vac/varicella/hcp-contraindications.htm
   Google Scholar
• Dominguez SR, Anderson MS. Advances in the treatment of Kawasaki disease. Curr Opin Pediatr. 2013;25:103–109.
   PubMed Web of Science ®Google Scholar
• Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168:181–185.
   PubMed Web of Science ®Google Scholar
• Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr. 2003;143:363–367.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663–675.
   PubMed Web of Science ®Google Scholar
• Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383:1731–1738.
   PubMed Web of Science ®Google Scholar
• Lau AC, Duong TT, Ito S, et al. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol. 2009;157:300–309.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Terai M, Hamada H, et al. Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30:871–876.
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Ott de Bruin LM, Borrow R, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European league against rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11:112–122.
   PubMed Web of Science ®Google Scholar